I hate to say this David, but you watch. lympro data will continue to be manipulated as a carrot on a string until such a point as we get an orphan approval back from the FDA on MANF. It makes absolutely no sense that we don't have the Lympro data NOW! After two years of feet dragging. Sadly, it is the way in which OTC CEO's get to the next level of development. I hope I am wrong, but I expect problems or something that puts off the bridge data. It's just business.